Recent developments include leadership changes with the appointment of Ian Blackman as CFO, execution of a material license agreement with Celularity, ongoing revenue growth, and Nasdaq listing compliance challenges.

• NexGel appointed Ian Blackman as Chief Financial Officer in April 2026, bringing over 30 years of financial leadership experience [N2][N3].
• The company entered into an Asset Purchase and Exclusive License Agreement with Celularity in March 2026, acquiring rights to a commercial-stage regenerative biomaterials portfolio with upfront and milestone payments totaling up to $35 million [S3][S4].
• NexGel completed a private placement in May 2026 issuing unsecured convertible promissory notes totaling $1.21 million and warrants exercisable for over 1 million shares to raise capital [S6][S21].
• The company reported a net loss of $927,000 and EPS of -$0.11 for Q1 2026, with liquidity ratios indicating a current ratio of 1.7 and cash ratio of 0.47 as of March 31, 2026 [S2].
• NexGel received a Nasdaq deficiency letter in April 2026 due to its stock price trading below the $1.00 minimum bid price requirement, with a compliance deadline of October 19, 2026 [S2].
• The company has demonstrated strong revenue growth in prior periods, including 181% growth in Q4 2024 and 112% for full year 2024, and expanded partnerships such as with STADA Arzneimittel AG [N6][N7].

NexGel has demonstrated strong revenue growth in recent years, including record growth in 2024 and doubling revenue in fiscal Q2 2025. The acquisition of Celularity's biomaterials portfolio provides a foundation for expanding its product offerings and market presence. Strategic partnerships, such as with STADA Arzneimittel AG, support the launch of new health solutions. The appointment of an experienced CFO with a strong financial leadership background may enhance financial management and capital raising capabilities. The company's liquidity position and access to convertible note financing provide resources to support ongoing operations and growth initiatives.

NexGel reported a net loss and negative EPS in Q1 2026, indicating ongoing profitability challenges. The company faces a Nasdaq listing deficiency due to its stock price trading below the minimum bid price requirement, which could lead to delisting if not resolved by October 2026. The reliance on milestone payments and licensing agreements introduces execution risk related to achieving sales targets. Convertible note financing and equity dilution may impact shareholder value. The company's emerging growth status and limited operating history in commercializing biomaterial products add to business risk.

NexGel's moat is derived from its exclusive license to Celularity's commercial-stage regenerative biomaterials portfolio, which provides proprietary access to a portfolio of biomaterial products and development-stage programs. The company's strategic partnerships and licensing agreements, along with milestone-based payments, create barriers to entry for competitors. Additionally, the expertise of its management and board in finance, biotech, and capital markets supports its ability to execute on growth strategies and navigate regulatory and market challenges.

• Nasdaq Listing Deficiency: The company's common stock has traded below the $1.00 minimum bid price required for continued listing on Nasdaq, with a compliance deadline of October 19, 2026. Failure to regain compliance could result in delisting.
• Profitability and Cash Flow: NexGel reported a net loss of $927,000 in Q1 2026 and negative EPS, indicating ongoing challenges in achieving profitability and positive cash flow.
• Execution Risk on Milestones: The acquisition agreement with Celularity includes milestone payments contingent on net sales targets, which introduces risk if sales targets are not met.
• Equity Dilution and Financing: The company has issued convertible notes and warrants, which may dilute existing shareholders and impose financial obligations.
• Emerging Growth Company Risks: As an emerging growth company, NexGel faces risks related to limited operating history, market acceptance, and regulatory challenges in the biomaterials sector.

• NexGel, Inc. is a Delaware corporation listed on The Nasdaq Capital Market under ticker NXGL and its warrants under NXGLW [S1].
• The company is an emerging growth company [S1].
• As of April 28, 2026, NexGel had 8,849,665 shares of common stock outstanding [S1].
• The company operates in the biomaterials and regenerative medicine sector, having acquired an exclusive license and assets related to Celularity's commercial-stage regenerative biomaterials portfolio and certain development-stage programs [S3, S4].
• The acquisition agreement with Celularity includes an upfront payment of $15 million and potential milestone payments up to $20 million based on net sales targets [S3, S4].
• NexGel has entered into ancillary agreements including contract manufacturing and sublease agreements related to the Celularity business [S3].
• The company completed a private placement in May 2026 issuing unsecured convertible promissory notes totaling $1.21 million and warrants exercisable for 1,008,334 shares, with terms similar to prior convertible notes issued in April 2026 [S6, S21].
• NexGel's liquidity as of March 31, 2026 includes $938,000 in cash and equivalents, $5,638,000 in current assets, and $3,314,000 in current liabilities, resulting in a current ratio of 1.7 and a cash ratio of 0.47 [S2].
• The company reported a net loss of $927,000 and basic and diluted EPS of -$0.11 for the quarter ended March 31, 2026 [S2].
• NexGel's board of directors includes experienced individuals with backgrounds in finance, biotech, and capital markets, including CEO Adam Levy and CFO Ian Blackman appointed in April 2026 [S1, N2, N3].
• The company has an Audit Committee with members qualified as independent directors and an audit committee financial expert [S1].
• NexGel received a Nasdaq deficiency letter in April 2026 due to its common stock closing price being below the $1.00 minimum bid price requirement for 30 consecutive business days, with a compliance period until October 19, 2026 [S2].
• NexGel has reported significant revenue growth in prior periods, including 181% growth in Q4 2024 and 112% for full year 2024, with revenue doubling in fiscal Q2 2025 [N6, N7].
• The company has expanded partnerships, including with STADA Arzneimittel AG to launch new health solutions [N7].
• Recent leadership changes include the appointment of Ian Blackman as CFO in April 2026, succeeding interim CFO Adam Drapczuk [N2, N3].
• NexGel's business model includes licensing, acquisition, and commercialization of biomaterial products with milestone-based payments and strategic partnerships [S3, N4].